Ziftomenib and mezigdomide for relapsed or refractory AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two experimental drugs, ziftomenib and mezigdomide, for people whose acute myeloid leukemia (AML) has come back or not responded to prior treatment. It's designed for those whose leukemia cells have a specific genetic change (KMT2A rearrangement or NPM1 mutation).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old (or 16 during the dose-finding part) and weigh at least 40 kg.
- Your AML must have either a KMT2A rearrangement or an NPM1 mutation, confirmed by specialized lab tests.
- Your cancer must have returned or not gotten better after at least one prior treatment.
- You must be in fairly good physical condition (ECOG score 0, 1, or 2, or similar scores for younger patients).
- Your heart, liver, and kidney function must meet certain minimum levels (like a heart pump strength of at least 40%).
- You cannot have active central nervous system leukemia, uncontrolled infections, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
Hear when a new KMT2A-rearranged trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.